Table 3.

Future lines of research with tramiprosate, ALZ-801, and 3-APS.

Disease-modifying treatments (amyloid pathology)
Tramiprosate	•Prospective observational studies with tramiprosate in aMCI and mild-moderate AD patients (phase IV)
ALZ-801	• aMCI and MA-MCI ApoE4/4 carriers (phase III, IV) • Mild AD ApoE4/4 carriers (phase III, IV) • ApoE4/4 carriers with non-AD neurodegenerative disorders:    ∘ Lewy Body Disease (phase II, III, IV)    ∘ Vascular dementia (phase II, III, IV)    ∘ Frontotemporal dementia (phase II, III, IV)    ∘ Parkinson-dementia (phase II, III, IV)
3-APS	• aMCI and MA-MCI ApoE4/4 carriers (phase II, III) • Mild and Moderate AD ApoE4/4 carriers (phase II, III)
Symptomatic treatment (central cholinergic dysfunction)
ALZ-801	• aMCI (ALZ-801 vs. placebo) • Mild and moderate AD (ALZ-801 vs. placebo with CEI) • Parkinson disease subtype: early gait disturbances, visual hallucination, dysphagia, REM Sleep Behavior Disorder, olfactory impairment, cognitive deterioration (ALZ-801 vs. placebo, with or without CEI) • Huntington disease (ALZ-801 vs. placebo) • Brain injuries (ALZ-801 vs. placebo with or without CEI) • Vascular cognitive deterioration (ALZ-801 vs. placebo) • Vascular dementia (ALZ−801 vs. placebo, with or without CEI) • Hippocampal atrophy no-AD (PART, LATE) (ALZ-801 vs. placebo)

3-APS, 3-amino-1-propanesulfonic acid; AD, Alzheimer disease; aMCI, amnestic MCI; ApoE4, Apolipoprotein E4, ε4 allele of the apolipoprotein E gene; CEI, cholinesterase inhibitor; LATE, Limbic-predominant age-related TDP-43 encephalopathy; MCI, MA-MCI, multi amnestic MCI; Mild Cognitive Impairment; PART, Primary age-related tauopathy.